Back to product search
$100.00
30μl
30μl -$100.00
100μl -$220.00
200μl -$360.00
RIDACOM Ltd. hotline:
Collagen IV Polyclonal Antibody
Antigen:
Collagen alpha-1(IV) chain
Synonyms: CO4A1_HUMAN; A7E2W4; B1AM70; F5H5K0; P02462; Q1P9S9; Q5VWF6; Q86X41; Q8NF88; Q9NYC5
Host:Rabbit
Reactivity:Human; Mouse; Rat
Application:Western Blotting; ELISA
Isotype:IgG
Clonality:Polyclonal
Description:
Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB: 1:500-2000, ELISA 1:10000-20000.
Purification:The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Formulation:Liquid solution
Precautions:
The product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.
Alternative:
collagen, type IV, alpha 1
Buffer form:PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Storage conditions:Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.
Delivery conditions:Gel pack with blue ice.
Immunogen:Synthesized peptide derived from Collagen IV . at AA range: 1620-1670
Usage:
COL4A1(collagen type IV alpha 1 chain) encodes a type IV collagen alpha protein. Type IV collagen proteins are integral components of basement membranes. COL4A1 shares a bidirectional promoter with a paralogous gene on the opposite strand. The protein consists of an amino-terminal 7S domain, a triple-helix forming collagenous domain, and a carboxy-terminal non-collagenous domain. It functions as part of a heterotrimer and interacts with other extracellular matrix components such as perlecans, proteoglycans, and laminins. In addition, proteolytic cleavage of the non-collagenous carboxy-terminal domain results in a biologically active fragment known as arresten, which has anti-angiogenic and tumor suppressor properties. Mutations in COL4A1 cause porencephaly, cerebrovascular disease, and renal and muscular defects. Alternative splicing results in multiple transcript variants.
Current View